Previous Close | 9.97 |
Open | 10.87 |
Bid | 9.15 |
Ask | 11.75 |
Strike | 132.00 |
Expire Date | 2024-06-07 |
Day's Range | 10.85 - 11.27 |
Contract Range | N/A |
Volume | |
Open Interest | 95 |
Eli Lilly may be riding high on its diabetes and weight-loss treatments Mounjaro and Zepbound — which Wall Street estimates could net the company $13.5 billion in 2024 — but the success comes with ongoing criticism about pricing and access.
These five companies may offer higher earnings and return potential with lower risk. Two Leaderboard stocks included.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.